Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Revvity Inc. Stock Advances 3.9%, Outperforms Peers

Revvity Inc. Stock Advances 3.9%, Outperforms Peers

Dow JonesDow Jones2026/08/20 20:35

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Revvity Inc. rallied 3.9% to $124.13 on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.9% to 7,641.16 and Dow Jones Industrial Average falling 1.3% to 52,759.21.

This was the stock's second consecutive day of gains.

Revvity Inc. hit a new 52-week high, surpassing its previous peak of $122.11, which the company achieved on August 19th.

The stock outperformed some of its peers, as Danaher Corp. rose 2.1% to $215.91, IDEXX Laboratories Inc. fell 2.9% to $545.86, and Agilent Technologies Inc. rose 0.57% to $156.30.

Trading volume totaled 2.3 million, compared to the 50-day average of 1.5 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

August 20, 2026 16:35 ET (20:35 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

UBS is bullish on CoreWeave (CRWV.US): Initiates "Buy" rating, betting on the return of AI trading rotation.

UBS has initiated coverage of the emerging cloud service provider CoreWeave (CRWV.US) with a "Buy" rating and set a target price of $120.

智通财经2026/09/24 07:01

Sixth increase in six years! Disney(DIS.US) raises the monthly fee for Disney+ ad-free version by 13% to $21.49.

Walt Disney Company (DIS.US) is raising subscription prices for several of its streaming services in the U.S. market, marking the sixth price increase in six years, as the company aims to boost the profitability of its streaming business, which is crucial for Disney's future.

智通财经2026/09/24 06:51

Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth

On September 24, according to the CDE website, Johnson & Johnson’s (JNJ.US) talquetamab (Chinese brand name: Tuolike) is proposed to be included in priority review.

智通财经2026/09/24 06:51
Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth